Veloxis Pharmaceuticals AS - Strategic SWOT Analysis Review

December 2020 | 31 pages | ID: V9594602EAE0EN
GlobalData

Abstracts

Veloxis Pharmaceuticals AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Veloxis Pharmaceuticals A/S (Veloxis), a subsidiary of Asahi Kasei Corp, is a specialty pharmaceutical company that identifies, develops and commercializes pharmaceutical drugs in transplantation and adjacent therapies. The company lead product is ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients. ENVARSUS is developed based on the company’s proprietary, patented drug delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company sells ENVARSUS XR to government agencies, specialty pharmacies, managed healthcare organizations, wholesalers and retail customers across the US, Europe and worldwide. Veloxis is headquartered in Copenhagen, Denmark.

Veloxis Pharmaceuticals AS Key Recent Developments

Jan 29,2020: Nasdaq Copenhagen has accepted Veloxis Pharmaceuticals request for Delisting of its Shares from Nasdaq Copenhagen
Nov 26,2019: Asahi Kasei offers to buy Veloxis Pharmaceuticals for $1.3bn
Nov 12,2019: Veloxis Pharmaceuticals announces financial results for the first nine months of 2019
Aug 08,2019: Veloxis Pharmaceuticals announces financial results for the first six months of 2019
Jul 22,2019: Veloxis revises outlook for 2019 based on strong performance

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents

Table of Contents
List of Tables
List of Figures

SECTION 1 - ABOUT THE COMPANY

Veloxis Pharmaceuticals AS - Key Facts
Veloxis Pharmaceuticals AS - Key Employees
Veloxis Pharmaceuticals AS - Key Employee Biographies
Veloxis Pharmaceuticals AS - Major Products and Services
Veloxis Pharmaceuticals AS - History
Veloxis Pharmaceuticals AS - Company Statement
Veloxis Pharmaceuticals AS - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Veloxis Pharmaceuticals AS - Business Description
Veloxis Pharmaceuticals AS - SWOT Analysis
SWOT Analysis - Overview
Veloxis Pharmaceuticals AS - Strengths
Veloxis Pharmaceuticals AS - Weaknesses
Veloxis Pharmaceuticals AS - Opportunities
Veloxis Pharmaceuticals AS - Threats
Veloxis Pharmaceuticals AS - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Veloxis Pharmaceuticals AS, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Jan 29, 2020: Nasdaq Copenhagen has accepted Veloxis Pharmaceuticals request for Delisting of its Shares from Nasdaq Copenhagen
Nov 26, 2019: Asahi Kasei offers to buy Veloxis Pharmaceuticals for $1.3bn
Nov 12, 2019: Veloxis Pharmaceuticals announces financial results for the first nine months of 2019
Aug 08, 2019: Veloxis Pharmaceuticals announces financial results for the first six months of 2019
Jul 22, 2019: Veloxis revises outlook for 2019 based on strong performance
May 06, 2019: Veloxis Pharmaceuticals announces financial results for the first three months of 2019
Feb 27, 2019: Veloxis Pharmaceuticals releases annual report for 2018
Jan 03, 2019: Mark Hensley promoted to Chief Commercial Officer of Veloxis Pharmaceuticals

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Veloxis Pharmaceuticals AS, Key Facts
Veloxis Pharmaceuticals AS, Key Employees
Veloxis Pharmaceuticals AS, Key Employee Biographies
Veloxis Pharmaceuticals AS, Major Products and Services
Veloxis Pharmaceuticals AS, History
Veloxis Pharmaceuticals AS, Subsidiaries
Veloxis Pharmaceuticals AS, Key Competitors
Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Veloxis Pharmaceuticals AS, Recent Deals Summary

List Of Figures

LIST OF FIGURES

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

COMPANIES MENTIONED

Astellas Pharma A/S
Genzyme Corp
Metkinen Oy
Novartis Pharmaceuticals UK Ltd
Quantum Genomics SA
Roche a/s
Sanofi-Aventis Canada Inc